Among the many topics covered in the full Q118 SCS Market Recap are:
In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth.
A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?
Medtronic’s Stacey Pugh discusses the Company’s new Riptide Aspiration System, new products in development, and growth strategies for the neurovascular business in a podcast interview with SmartTRAK at the International Stroke Conference (ISC) 2018 held Jan. 24-26, 2018 in Los Angeles, CA.
Anne Staylor here with BioMedGPS. We're at the International Stroke Conference in Los Angeles, and today I'm talking with Stacey Pugh of Medtronic Neurovascular. Hi Stacey, thanks for joining me.
In the market for stroke devices, Europe seems to be the proving ground for next generation devices, and several companies with novel technologies are emerging from Europe that could potentially reach the US market in the next several years. One European company taking aim at the US market is Bochum, Germany-based phenox GmbH.
The US Spinal Cord Stimulation market reached new heights in Q417/FY17, driven by new products, expanding indications, and a growing demand for non-narcotic alternatives for treating chronic intractable pain.SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 US Spinal Cord Stimulation Market Recap and Financial Dashboard.
Among the many topics covered in the Q417/FY17 Spinal Cord Stimulation Market Recap are:
SmartTRAK is excited to be attending NANS 2018 - the North American Neuromodulation Society's 21st Annual Meeting meeting on Jan 11-14, 2018 at Caesars Palace in Las Vegas, Nevada.
While the overall Neuromodulation Spinal Cord Stimulation (SCS) market continues to see strong, double-digit growth YTD, sequentially the US SCS market decelerated in Q317 due to seasonality and hurricane-related supply chain disruptions, particularly affecting Medtronic.
By Anne Staylor, Managing Editor, SmartTRAK Business Intelligence
YTD, the US SCS market is trending at high growth rates, a faster growth than SmartTRAK’s original 2017 forecast, as next generation products continue to drive unprecedented growth in this highly underpenetrated market. In the US, Abbott, Nevro and Boston Scientific’s (BSX) Q317 YoY SCS revenues increased respectively, while competitive pressures accelerated Medtronic’s US SCS revenue decline, down YoY according to SmartTRAK Financial Dashboard.
Kas Amirdelfan, MD talked with SmartTRAK at the ASRA 2017 Annual Meeting regarding preliminary 12 month results from the SENZA-ULN study
Kas Amirdelfan, MD, principle investigator of the SENZA-Upper Limb and Neck (ULN) study, spoke with SmartTRAK's Anne Staylor at the recent American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting in Lake Buena Vista, FL regarding preliminary 12 month results from SENZA-ULN, the unmet clinical need for chronic intractable ULN pain, factors affecting physician adoption for this indication and what’s next for this research. (See ASRA Poster 4194.)
A transcript of SmartTRAK’s interview with Dr. Amirdelfan is below or click on the following video to view the interview recorded live at ASRA 2017. (13:23 minutes.)
Leonardo Kapural, MD discusses interim results from SENZA-CAP in a SmartTRAK interview at ASRA 2017
At the recent American Society of Regional Anesthesia and Pain Medicine (ASRA)
annual meeting in Lake Buena Vista, FL, Leonardo Kapural, MD, professor of anesthesiology at Wake Forest University and principle investigator of the SENZA-RCT, presented interim three month results from SENZA-CAP, a multicenter feasibility study evaluating use of 10 kHz spinal cord stimulation (SCS) for the treatment of chronic abdominal pain (CAP). (See ASRA Poster 4491.)
In an interview at ASRA, SmartTRAK spoke to Dr. Kapural regarding key findings from this study, the addressable market for SCS in chronic abdominal pain, patient engagement as a potential variable, and what’s next for this research.
A transcript of SmartTRAK’s interview with Dr. Kapural is below. Or click on the following video to view the interview recorded live at ASRA 2017. (12:06 minutes.)
Closed-Loop Spinal Cord Stim: The Next Big Thing?
With impressive preliminary data from Saluda Medical’s AVALON trial, and all the big players working on evoked potentials, will closed-loop spinal cord stimulation (#SCS) be the next big thing?